Selecta Biosciences (NASDAQ: SELB) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Selecta Biosciences to related companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, risk and dividends.
This table compares Selecta Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Selecta Biosciences Competitors||-5,585.47%||-160.76%||-35.81%|
This table compares Selecta Biosciences and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Selecta Biosciences||$8.08 million||-$36.21 million||-2.83|
|Selecta Biosciences Competitors||$293.65 million||$35.70 million||71.14|
Selecta Biosciences’ competitors have higher revenue and earnings than Selecta Biosciences. Selecta Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
54.8% of Selecta Biosciences shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 41.9% of Selecta Biosciences shares are owned by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Selecta Biosciences and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Selecta Biosciences Competitors||1214||3583||12107||251||2.66|
Selecta Biosciences currently has a consensus target price of $29.00, indicating a potential upside of 231.05%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.33%. Given Selecta Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Selecta Biosciences is more favorable than its competitors.
Selecta Biosciences beats its competitors on 7 of the 12 factors compared.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.